Effect of Ramipril on Mortality and Morbidity of Survivors of Acute Myocardial Infarction Complicated by Heart Failure (AIRE)
Source: View publication →
The AIRE study demonstrated that early administration of the ACE inhibitor ramipril significantly reduces all-cause mortality and progression to severe heart failure in patients with clinical heart failure following an acute myocardial infarction.
Key Findings
Study Design
Study Limitations
Clinical Significance
The AIRE study established ACE inhibition as a standard-of-care therapy for patients with acute myocardial infarction complicated by clinical heart failure, significantly improving survival and reducing the progression of heart failure symptoms.
Historical Context
Published in the early 1990s, the AIRE trial was a landmark investigation that complemented findings from the SAVE study (which focused on asymptomatic left ventricular dysfunction), providing critical evidence for the broad application of ACE inhibitors in the post-myocardial infarction setting.
Guided Discussion
High-yield insights from every perspective
How does the inhibition of the renin-angiotensin-aldosterone system (RAAS) by ramipril prevent 'ventricular remodeling' in the weeks following an acute myocardial infarction?
Key Response
Following an MI, the heart undergoes structural changes (remodeling) driven by Angiotensin II, which promotes myocyte hypertrophy and collagen deposition (fibrosis). By blocking the conversion of Angiotensin I to II, ramipril reduces these deleterious structural changes, thereby preventing the progression to dilated cardiomyopathy and chronic heart failure.
The AIRE trial initiated ramipril between day 3 and day 10 post-MI. In modern clinical practice, what are the primary hemodynamic and renal parameters that must be stabilized before starting an ACE inhibitor in a patient who presented with Killip Class II heart failure?
Key Response
Before initiation, patients must be hemodynamically stable without the need for pressors, have a systolic blood pressure typically >100 mmHg to avoid hypotension-induced coronary hypoperfusion, and have stable renal function (serum creatinine <2.5 mg/dL and potassium <5.0 mEq/L) to prevent acute kidney injury and life-threatening hyperkalemia.
Compare the inclusion criteria of AIRE with the SAVE trial. How does selecting patients based on 'clinical evidence of heart failure' (AIRE) rather than a 'left ventricular ejection fraction ≤40%' (SAVE) impact the risk profile of the enrolled population and the observed Absolute Risk Reduction (ARR)?
Key Response
AIRE focused on clinical symptoms (Killip class), which often identifies a higher-risk cohort than LVEF alone. Clinical heart failure signs post-MI are powerful predictors of mortality. Consequently, AIRE demonstrated a very high ARR (mortality reduced from 23% to 17%), showing that clinical phenotype is as vital as imaging parameters for identifying patients who derive the greatest benefit from ACE inhibition.
The AIRE study demonstrated a 27% reduction in all-cause mortality. How should these findings influence the decision to continue ACE inhibitor therapy indefinitely in a patient whose post-MI heart failure symptoms (e.g., pulmonary rales) were only transient and resolved before discharge?
Key Response
A key finding of AIRE was that even transient heart failure during the acute phase of MI identifies a high-risk group that benefits significantly from long-term ACE inhibition. The mortality benefit is sustained over years; therefore, therapy should be continued indefinitely regardless of whether the clinical symptoms of heart failure resolved during the index hospitalization.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The AIRE trial utilized all-cause mortality as its primary endpoint. Analyze the trade-offs between using all-cause mortality versus a composite endpoint (e.g., cardiovascular death, MI, or HF hospitalization) in terms of statistical power, required sample size, and susceptibility to adjudication bias.
Key Response
All-cause mortality is the most 'honest' endpoint as it is not subject to investigator adjudication bias or competing risk misclassification. However, because it is an infrequent event compared to composite endpoints, it requires a larger sample size or longer follow-up to achieve adequate statistical power. AIRE’s ability to show a significant difference in all-cause mortality highlights the profound effect size of ramipril in this specific high-risk population.
The AIRE trial recruited patients 3 to 10 days post-MI. As a reviewer, what concerns would you raise regarding 'survivor bias' and how might this affect the internal validity and the generalizability of the results to the immediate (0-48 hour) post-MI period?
Key Response
By waiting at least 3 days to enroll, the study naturally excludes patients who died or had catastrophic complications in the hyper-acute phase. While this ensures the study population is stable enough to tolerate ACEI titration, it creates a 'healthy survivor' effect, meaning the results specifically apply to those who survive the initial insult, and the findings cannot be extrapolated to support ultra-early initiation (within hours) of high-dose ACE inhibitors.
Current AHA/ACC STEMI guidelines give ACE inhibitors a Class I (Level A) recommendation for patients with heart failure or LVEF <40%. How does the AIRE trial support this recommendation compared to the CONSENSUS II trial, which investigated earlier initiation of IV enalaprilat?
Key Response
AIRE provided the definitive Level A evidence for oral ACEI benefit in the clinical HF subgroup, showing mortality reduction when started after 48-72 hours. In contrast, CONSENSUS II showed that ultra-early IV ACE inhibition could be harmful (hypotension). This led to the guideline nuances: start ACEIs early (within 24 hours) via the oral route in stable patients, but avoid the IV route and ensure hemodynamic stability, as emphasized by the AIRE protocol timing.
Clinical Landscape
Noteworthy Related Trials
SOLVD-Treatment Trial
Tested
Enalapril
Population
Patients with symptomatic heart failure and ejection fraction <= 35%
Comparator
Placebo
Endpoint
All-cause mortality
SAVE Trial
Tested
Captopril
Population
Patients with left ventricular dysfunction after myocardial infarction
Comparator
Placebo
Endpoint
All-cause mortality
TRACE Trial
Tested
Trandolapril
Population
Patients with left ventricular dysfunction after myocardial infarction
Comparator
Placebo
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis